Abstract:Objective A meta-analysis of randomised controlled trials on the efficacy and safety in patients with Gram-positive cocci infections treated with linezolid versus with vancomycin.Methods The data were collected from the MEDLINE,EMBASE,OVID,the Cochrane library,and CNKI.We also handsearched relevant journals.Randomized controlled trials comparing linezolid with vancomycin in patients with Gram-positive cocci infections were eligible for inclusion.Two investigators independently assessed the quality and extracted the data.The methodological quality of trails was assessed by the Jadad-scale plus allocation concealment.Heterogeneity was examined by chi-square test.Fixed effects model or random effects model were used to pool the data.Sensitivity analyses were used in the treatment course.Results Twelve randomized controlled studies comparing linezolid with vancomycin were analyzed,focusing on the 5,863 patients with Gram-positive cocci infections.It was found by meta-analysis that,with respect to clinical treatment success,linezolid was more effective than vancomycin in clinically evaluation patients at the end-of-treatment visit [OR 1.98,95%CI(1.32,2.98),P=0.001] and at the test-of-cure visit [OR 1.34,95%CI(1.01,1.76),P=0.04],and there was more effective than vancomycin in intention-to-treat patients at the test-of-cure visit [OR 1.20,95%CI(1.01,1.43),P=0.04].With respect to microbiological treatment success,linezolid was more effective than vancomycin in microbiologically evaluation patients at the test-of-cure visit [OR 1.39,95%CI(1.12,1.73),P=0.003].Additionally,empirical treatment with linezolid was associated with increased eradication rates for S.aureus strains [OR=1.84,95%CI(1.39,2.42),P<0.0001] and enterococcal species [OR=5.42,95%CI(1.49,19.71),P=0.01] in comparison with vancomycin in microbiologically evaluation patients at the test-of-cure visit.But,there was no difference in eradication rates for MRSA strains [OR=1.54,95%CI(0.97,2.45),P=0.07],Streptococcal species [OR=0.89,95%CI(0.31,2.54),P=0.82].Mortality was similar between the groups [OR=1.07,95%CI(0.89,1.28),P=0.50].Treatment with linezolid was not associated with more adverse effects in general in comparison with vancomycin [OR=1.10,95%CI(0.83,1.44),P=0.52].Conclusion Linezolid is more effective than vancomycin for treatment of patients with Gram-positive cocci infections although rigorously designed large sample size randomized double blind clinical trials are required to further demonstrate and support the conclusion.

Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin–Resistant Enterococcus faecium in a Hollow Fiber Infection Model

In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus Faecalis

Factorial design and post-antibiotic sub-MIC effects of linezolid combined with fosfomycin against vancomycin-resistant enterococci

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model

In Vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci

Progress on the Resistance Mechanism of Enterococcus to Linezolid

Synergistic effect of linezolid with fosfomycin against Staphylococcus aureus in vitro and in an experimental Galleria mellonella model

Fosfomycin Resistance among Vancomycin-Resistant Enterococci Owing to Transfer of a Plasmid Harbouring the Fosb Gene.

The Synergistic Activity of Rhamnolipid Combined with Linezolid against Linezolid-Resistant Enterococcus faecium

Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature

The in vitro activity of linezolid against vancomycin-susceptible and-resistant Enterococcus faecium

In Vitro Pharmacodynamics of Fosfomycin against Carbapenem-Resistant Enterobacter cloacae and Klebsiella aerogenes

Linezolid and Rifampicin Combination to Combat Cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection

Combining Colistin with Furanone C-30 Rescues Colistin Resistance of Gram-Negative Bacteria in Vitro and in Vivo

In-vitro resensitization of multidrug resistant clinical isolates of Enterococcus faecium and faecalis through phage-antibiotic synergy

Linezolid Versus Vancomycin for Meticillin-Resistant Staphylococcus Aureus Infection: a Meta-Analysis of Randomised Controlled Trials.

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations

Increased Activity of Linezolid in Combination with Rifampicin in a Murine Pneumonia Model Due to MRSA.

Linezolid versus vancomycin for treatment of Gram-positive cocci infections:Meta-analysis of randomised controlled trials

In Vitro Activities of Daptomycin Combined with Fosfomycin or Rifampin on Planktonic and Adherent Linezolid-Resistant Isolates of Enterococcus Faecalis.

Antibacterial Activity of Fosfomycin in Combination with Eight Antimicrobial Agents Against Carbapenem-Resistant Enterobacteriaceae